Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Current Signal: SELL (auto-tracking)
7.67% $12.36
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 763.29 mill |
EPS: | -0.810 |
P/E: | -15.26 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 61.76 mill |
Avg Daily Volume: | 0.523 mill |
RATING 2024-03-27 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -15.26 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.07x |
Company: PE -15.26 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 11.66 - 13.08 ( +/- 5.71%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Berutti Aaron | Sell | 711 | Common Stock |
2024-03-10 | Berutti Aaron | Sell | 1 815 | Common Stock |
2024-03-08 | Hair Mark | Sell | 1 067 | Common Stock |
2024-03-10 | Hair Mark | Sell | 4 088 | Common Stock |
2024-03-08 | Treace John T. | Sell | 2 064 | Common Stock |
INSIDER POWER |
---|
-1.68 |
Last 99 transactions |
Buy: 1 598 706 | Sell: 2 038 924 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $12.36 (7.67% ) |
Volume | 0.509 mill |
Avg. Vol. | 0.523 mill |
% of Avg. Vol | 97.33 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $15.00 | N/A | Active |
---|
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.